Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA101 inhaled cromolyn sodium crossover study in indolent systemic mastocytosis
NL-OMON41987Phase 2Active, not recruiting
- Sponsor
- Patara Pharma
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RVT-1601 in indolent systemic mastocytosis (ISM) (4 cohorts), sponsored by Patara Pharma. Primary endpoint: Change from baseline in total symptom score. Started Jul 2015; status: active, not recruiting.
02
Drugs
RVT-1601
03
Conditions
indolent systemic mastocytosis (ISM)
Beyond the preview
Go deeper on NL-OMON41987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41987.